Log in to search using one of your social media accounts:

 

National cooperative group trial seeks to cut in half early mortality rates for rare leukemia
(Medical College of Georgia at Augusta University) A national cooperative group trial is making a handful of the country's experts in a rare leukemia available around the clock, with the goal of cutting by more than half the high mortality rates that occur in the difficult first few weeks of treatment.Induction mortality for treatment of acute promyelocytic leukemia, or APL, can be as high as 30 percent, but for patients who survive those first few weeks, survival rates can soar beyond 90 percent, making it the most curable leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 20, 2017 Category: International Medicine & Public Health Source Type: news

Seattle Children's opens first pediatric CAR T-Cell trial targeting CD22 and CD19 proteins
(Seattle Children's) Seattle Children's has opened the first chimeric antigen receptor (CAR) T-cell immunotherapy trial in the US for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia (ALL) that will simultaneously attack two targets on cancer cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 16, 2017 Category: International Medicine & Public Health Source Type: news

CHLA is awarded more than $1M from St. Baldrick's Foundation to fund cancer research
(Children's Hospital Los Angeles) Three physician-researchers with the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles (CHLA) have been awarded more than $1 million in grants from the St. Baldrick's Foundation, the largest private funder of childhood cancer research. The funding will be used to support research efforts spanning both neuroblastoma and acute lymphoblastic leukemia -- two of the most aggressive childhood cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 14, 2017 Category: Cancer & Oncology Source Type: news

CHLA is awarded more than $1 million from St. Baldrick's Foundation to fund cancer research
(Children's Hospital Los Angeles) Three physician-researchers with the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles (CHLA) have been awarded more than $1 million in grants from the St. Baldrick's Foundation, the largest private funder of childhood cancer research. The funding will be used to support research efforts spanning both neuroblastoma and acute lymphoblastic leukemia -- two of the most aggressive childhood cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 14, 2017 Category: Cancer & Oncology Source Type: news

MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia
Activating mutations in the gene encoding the cell-cell contact signaling protein Notch1 are common in human T cell acute lymphoblastic leukemias (T-ALLs). However, expressing Notch1 mutant alleles in mice fails to efficiently induce the development of leukemia. We performed a gain-of-function screen to identify proteins that enhanced signaling by leukemia-associated Notch1 mutants. The transcription factors MAFB and ETS2 emerged as candidates that individually enhanced Notch1 signaling, and when coexpressed, they synergistically increased signaling to an extent similar to that induced by core components of the Notch trans...
Source: Signal Transduction Knowledge Environment - November 14, 2017 Category: Science Authors: Pajcini, K. V., Xu, L., Shao, L., Petrovic, J., Palasiewicz, K., Ohtani, Y., Bailis, W., Lee, C., Wertheim, G. B., Mani, R., Musuthamy, N., Li, Y., Meijerink, J. P. P., Blacklow, S. C., Faryabi, R. B., Cherry, S., Pear, W. S. Tags: STKE Research Articles Source Type: news

Are You Sure That's What the Doctor Said About Your Leukemia?
Source: HealthDay Related MedlinePlus Pages: Acute Myeloid Leukemia, Talking With Your Doctor (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 3, 2017 Category: Consumer Health News Source Type: news

Are You Sure That's What the Doctor Said About Your Leukemia?
THURSDAY, Nov. 2, 2017 -- The stress of a frightening leukemia diagnosis may impede clear doctor-patient communication, a new study suggests. Patients undergoing chemotherapy treatment for acute myeloid leukemia (AML) tend to view their illness and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 2, 2017 Category: General Medicine Source Type: news

Papers of note in Science Translational Medicine 9 (413)
This week’s articles describe new therapeutic targets for pulmonary arterial hypertension, acute myeloid leukemia, and Friedreich’s ataxia. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - October 31, 2017 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

Blocking key pathways is a way to defeat cancer stem cells
(RIKEN) Scientists from the RIKEN Center for Integrative Medical Sciences in Japan and international collaborators have found that in humanized mice, a cocktail of drugs blocking certain key pathways is effective in eliminating acute myeloid leukemia (AML), a disease which is estimated to kill more than 250,000 people a year around the world. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 25, 2017 Category: Cancer & Oncology Source Type: news

Leukemia Patients Who Survive Severe GVHD Often Fare Worse
Those who develop severe acute graft - versus - host after stem cell transplant have higher mortality (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 23, 2017 Category: Cancer & Oncology Tags: Internal Medicine, Critical Care, Nursing, Oncology, Pathology, Journal, Source Type: news

People with leukemia and their oncologists have vastly different perceptions of prognosis
(American Society of Clinical Oncology) A study of 100 people with acute myeloid leukemia (AML) receiving chemotherapy found that patient and physician perceptions of treatment risk and the likelihood of a cure varied widely. Overall, patients tended to overestimate both the risk of dying due to treatment and the likelihood of a cure. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 23, 2017 Category: Cancer & Oncology Source Type: news

Bolstering fat cells offers potential new leukemia treatment
(McMaster University) Killing cancer cells indirectly by powering up fat cells in the bone marrow could help acute myeloid leukemia patients, says a study from McMaster University published in Nature Cell Biology. Researchers with the McMaster Stem Cell and Cancer Research Institute found that boosting adipocytes, or fat cells, located in the bone morrow suppressed cancerous leukemia cells but -- in a surprise to the research team -- also induced the regeneration of healthy blood cells. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 16, 2017 Category: Biology Source Type: news

Childhood Acute Lymphoblastic Leukemia (ALL)
Title: Childhood Acute Lymphoblastic Leukemia (ALL)Category: Diseases and ConditionsCreated: 10/28/2009 12:00:00 AMLast Editorial Review: 10/11/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 11, 2017 Category: Cancer & Oncology Source Type: news

BU researcher receives grant to better understand lymphoblastic leukemia
(Boston University School of Medicine) Hui Feng, M.D., Ph.D., assistant professor of pharmacology and medicine at Boston University School of Medicine (BUSM), is the recipient of a four-year, $792,000 grant from the American Cancer Society to study why T-cell acute lymphoblastic leukemia (T-ALL) is so aggressive and resistant to treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 10, 2017 Category: Cancer & Oncology Source Type: news

Novel Treatment Causes Cancer to Self-Destruct Without Affecting Healthy Cells
October 9, 2017—BRONX, NY—Scientists atAlbert Einstein College of Medicine have discovered the first compound that directly makescancer cells commit suicide while sparing healthy cells. The new treatment approach, described in today’s issue of Cancer Cell, was directed against acute myeloid leukemia (AML) cells but may also have potential for attacking other types of cancers. (Source: Einstein News)
Source: Einstein News - October 9, 2017 Category: Universities & Medical Training Source Type: news

Medical News Today: New compound kills cancer without harming healthy cells
A proof-of-concept study shows how a new compound selectively triggers cell suicide in acute myeloid leukemia cells without harming healthy cells. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 9, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Stealing from the body: How cancer recharges its batteries
(University of East Anglia) New research published today uncovers how the blood cancer 'steals' parts of surrounding healthy bone marrow cells to thrive, in work that could help form new approaches to cancer treatment in the future. Researchers at the University of East Anglia (UEA), funded by the Rosetrees Trust and The Big C Charity, found that healthy bone marrow stromal cells were made to transfer their power-generating mitochondria to neighbouring cancer cells, effectively 'recharging' the acute myeloid leukaemia (AML) and supporting the leukaemia to grow. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 5, 2017 Category: Cancer & Oncology Source Type: news

Rates and Trends of Pediatric Acute Lymphoblastic Leukemia Rates and Trends of Pediatric Acute Lymphoblastic Leukemia
This report examines the latest demographic and geographic trends in ALL incidence among children and adolescents in the U.S.Morbidity & Mortality Weekly Report (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

BioLineRx launches Phase Ib/II combination trial for acute myeloid leukaemia
Israeli biopharmaceutical firm BioLineRx has launched a Phase Ib/II clinical trial (BATTLE) of BL-8040 in combination with Genentech ’s anti-PDL1 immunotherapy atezolizumab (Tecentriq) in patients suffering from acute myeloid leukaemia (AML). (Source: Drug Development Technology)
Source: Drug Development Technology - September 27, 2017 Category: Pharmaceuticals Source Type: news

HLA-mismatched Microtransplant Benefits Older AML Patients HLA-mismatched Microtransplant Benefits Older AML Patients
Most older patients with newly diagnosed acute myeloid leukemia (AML) achieve complete remission and good overall survival after HLA-mismatched microtransplant, according to results from 12 centers in China, the United States, and Spain.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 20, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

How to manage family life when your child has cancer
Valerie, with husband Doron, son Evan and daughter Ruby When our daughter, Ruby, was diagnosed with acute lymphoblastic leukemia (ALL) at one and a half years old, my husband and I were immediately transformed from working parents with two young children, to parental caregivers for a child with cancer. Between hospital stays, medications and appointments, there was so much to keep track of. It can be overwhelming at times, but there are ways to manage life after your child is diagnosed with cancer. Settle into to this new normal. It can be easy to stay in crisis mode when something like a cancer diagnosis interrupts y...
Source: Thrive, Children's Hospital Boston - September 20, 2017 Category: Pediatrics Authors: Valerie Graf Tags: Diseases & Conditions Parenting Cancer Dana-Farber/Boston Children's Cancer and Blood Disorders Center Source Type: news

Novartis's Rydapt wins EU approval for AML, other diseases
ZURICH (Reuters) - Swiss drugmaker Novartis on Wednesday said it had won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals it secured in April. (Source: Reuters: Health)
Source: Reuters: Health - September 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

'Capicua' gene plays a key role in T-cell acute lymphoblastic leukaemia
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Researchers at the Spanish National Cancer Research Centre (CNIO) have discovered a genetic alteration that is directly involved in at least 10% of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukaemia. In a paper published this week in the printed edition of Genes and Development, the scientists explain how the mice in which a specific gene, known as Capicua, has been inactivated, inevitably develop this type of leukaemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

'Capicua' gene plays a key role in T-cell acute lymphoblastic leukemia
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Researchers at the Spanish National Cancer Research Centre have discovered a genetic alteration that is directly involved in at least 10 percent of cases of one of the most common cancers in children, T-cell acute lymphoblastic leukemia. In a paper published this week in the printed edition of Genes and Development, the scientists explain how the mice in which a specific gene, known as Capicua, has been inactivated, inevitably develop this type of leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 20, 2017 Category: Cancer & Oncology Source Type: news

Formula Pharmaceuticals initiates Phase I/IIa trial of allogeneic CIK cells for ALL
US-based immuno-oncology company Formula Pharmaceuticals has initiated a Phase I/IIa clinical trial of allogeneic, cytokine-induced killer (CIK), cell-based chimeric antigen receptor (CAR) cancer immunotherapy for acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 19, 2017 Category: Pharmaceuticals Source Type: news

GATA1 as a Marker for Erythroid and Megakaryocytic Lineages GATA1 as a Marker for Erythroid and Megakaryocytic Lineages
This study investigated the use of GATA binding factor 1 as a marker for neoplastic cells of pure erythroleukemia and acute megakaryoblastic leukemia.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Rates and Trends of Pediatric Acute Lymphoblastic Leukemia — United States, 2001–2014
(Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - September 14, 2017 Category: American Health Source Type: news

Adult Acute Lymphoblastic Leukemia (ALL)
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 14, 2017 Category: General Medicine Source Type: news

MD Anderson and Daiichi Sankyo enter research collaboration to accelerate development of acute myeloid leukemia therapies
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited today announced a multi-year collaboration focused on accelerating the development of novel therapies for acute myeloid leukemia (AML). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2017 Category: International Medicine & Public Health Source Type: news

Pascal Biosciences acquires STC technology for B-cell precursor ALL treatment
Canadian drug discovery and development company Pascal Biosciences has executed an exclusive, worldwide licence option agreement with STC.UNM (STC) to purchase a therapeutic monoclonal antibody for B-cell precursor acute lymphoblastic leukaemia (BCP- … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia
Kymriah (tisagenlecleucel) is the first chimeric antigen receptor T cell (CAR-T) therapy approved in the US for the treatment of paediatric and young adult patients with B-cell precursor acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news

Inhibitors support immune therapy for leukemia
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) New immune therapies are considered a promising lead for treating recurring acute myeloid leukemia (AML). Antibodies are able to eliminate even those cancer cells that cannot be removed via regular therapies. Scientists from the German Cancer Consortium (DKTK) and the Munich University Hospital and T ü bingen University Hospital have shown that, in conjunction with certain inhibitors, this form of therapy could be successful in even more patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

FDA approves Mylotarg to treat acute myeloid leukemia
The U.S. Food and Drug Administration approved Mylotarg, or gemtuzumab, for the treatment of adults with newly diagnosed acute myloid leukemia. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 5, 2017 Category: Consumer Health News Source Type: news

Pfizer ’s Mylotarg receives FDA approval for acute myeloid leukaemia treatment
The US Food and Drug Administration (FDA) has granted approval to Pfizer ’s antibody-drug conjugate (ADC) Mylotarg (gemtuzumab ozogamicin) for the treatment of patients with acute myeloid leukaemia (AML). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 3, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves Mylotarg (gemtuzumab ozogamicin) for the Treatment of Acute Myeloid Leukemia
September 1, 2017 -- The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 1, 2017 Category: Drugs & Pharmacology Source Type: news

FDA OKs Return of Once-Withdrawn Leukemia Drug
At lower dose, Mylotarg extended survival against a certain type of blood cancer Source: HealthDay Related MedlinePlus Pages: Acute Myeloid Leukemia, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - September 1, 2017 Category: Consumer Health News Source Type: news

Mylotarg Back on Market with New FDA Approval
(MedPage Today) -- Smaller doses OK'd for certain acute myeloid leukemia indications (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 1, 2017 Category: American Health Source Type: news

Mylotarg Approved for AML: Drug Returns to Market Mylotarg Approved for AML: Drug Returns to Market
After being voluntarily withdrawn 7 years ago, gemtuzumab ozogamicin (Mylotarg) is now returning to the market for the treatment of acute myeloid leukemia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA OKs Return of Once-Withdrawn Leukemia Drug, Mylotarg
FRIDAY, Sept. 1, 2017 -- The U.S. Food and Drug Administration on Friday approved an altered dose of the drug Mylotarg to treat a distinctive type of acute myeloid leukemia -- CD33-positive AML. An earlier version of the drug had been withdrawn... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 1, 2017 Category: General Medicine Source Type: news

FDA approves Pfizer's leukemia drug
(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc's drug, Mylotarg, for certain patients with acute myeloid leukemia (AML). (Source: Reuters: Health)
Source: Reuters: Health - September 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves Mylotarg for treatment of acute myeloid leukemia
SILVER SPRING, Md., Sept. 1, 2017 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors expres... Biopharmaceuticals, Oncology, FDA Pfizer, Mylotarg, gemtuzumab ozogamicin, acute myeloid leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 1, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Mylotarg for treatment of acute myeloid leukemia
The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 1, 2017 Category: American Health Source Type: news

Weekly Postings
See something of interest? Please share our postings with colleagues in your institutions! Spotlight Update your membership record today! If you complete the renewal process by Friday, September 8, you can expect to receive your certificate by the end of the month. If you have not yet verified that your organization’s record is up-to-date, check out our Membership renewal flyer for more information. National Preparedness Month begins today! Visit the Ready Campaign web page to learn about this year’s theme, “Disasters Don’t Plan Ahead. You Can” and check out the 2017 promotional toolkit which ...
Source: NN/LM Middle Atlantic Region Blog - September 1, 2017 Category: Databases & Libraries Authors: Hannah Sinemus Tags: Weekly Postings Source Type: news

A parent ’s guide to clinical trials
Children with life-threatening conditions, such as cancer, are often candidates for clinical trials. What are they? Which factors should parents weigh in determining whether enrolling in one is a good option for their child? Dr. Steven DuBois, director of the Advancing Childhood Cancer Therapies Clinic at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, answers questions about clinical trials. What are clinical trials? Why are they important? Clinical trials are systematic, scientific investigations of new drugs or therapies for a specific disease. Through clinical trials, we have taken many fatal ped...
Source: Thrive, Children's Hospital Boston - September 1, 2017 Category: Pediatrics Authors: Irene Sege Tags: Ask the Expert Research and Innovation clinical trial Dana-Farber/Boston Children's Cancer and Blood Disorders Center Dr. Steven DuBois Source Type: news

FDA approves Mylotarg for treatment of acute myeloid leukemia
The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory). (Source: World Pharma News)
Source: World Pharma News - September 1, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Novartis ’ Kymriah receives FDA approval for B-cell precursor ALL treatment
The US Food and Drug Administration (FDA) has approved Novartis ’ Kymriah (tisagenlecleucel) suspension for intravenous infusion to treat patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia (ALL) that is refractory or in… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 31, 2017 Category: Pharmaceuticals Source Type: news

Medical News Today: Acute myeloid leukemia: Heart drugs may boost chemotherapy
Researchers find that drugs normally used to treat heart and blood vessel disease could also help to improve chemotherapy outcomes for patients with AML. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 31, 2017 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

FDA Approves Therapy Using Patient ’ s Own Cells To Fight Cancer Cells
BOSTON (CBS) — The Dana Farber Cancer Institute and Boston Children’s Hospital will work to fight cancer in a new way thanks to a new treatment approved by the FDA. CAR-T therapy is for kids and young adults with relapsed and refractory acute lymphoblastic leukemia (ALL). “It’s really an entirely new type of therapy, an entirely new way to fight cancer,” said Dr. Lewis Silverman, the Clinical Director of the Pediatric Hematologic Malignancies Center. Chemotherapy drugs attack dividing cells but are not specific to cancer cells, unlike this new treatment, according to Silverman. “It&...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 31, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Seen On WBZ-TV Syndicated Local Boston Children's Hospital Dana Farber Cancer Institute Juli McDonald Leukemia Source Type: news

First Gene Therapy Approved in U.S. (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM The FDA on Wednesday approved tisagenlecleucel (Kymriah) for patients up to age 25 years with B cell precursor acute lymphoblastic leukemia that has relapsed or not responded … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 30, 2017 Category: Primary Care Source Type: news

HealthWatch: A New Gene Therapy For Leukemia; A Study On Carbohydrates
This study does not mean you can now eat a ton of butter and steak without worry, but you probably don’t need to feel guilty about eating some fat. In terms of carbohydrates, the study did not distinguish between refined carbs and complex carbs, so further study is needed. (Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire)
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 30, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Healthwatch Local News Seen On WBZ-TV Syndicated Local Cancer Research Dr. Mallika Marshall Leukemia Source Type: news